Accepted abstract by ICML with updated results from Phase 1/2 trial of Betalutin® in NHL is now available on-line
Oslo, Norway, 7 June 2017 Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting updated results from the ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) accepted for a presentation at the International Conference on Malignant Lymphoma (ICML; 14-17 June; Lugano, Switzerland), is now available on-line – http://onlinelibrary.wiley.com/doi/10.1002/hon.v35.S2/issuetoc An updated dataset on 59 patients (safety) and 47 patients (efficacy) will be presented in a poster